Healthcare Press

AstraZeneca's Roxadustat receives China approval

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

AstraZeneca PLC (AZN.LN) said Tuesday that its drug roxadustat has been approved in China as a treatment for patients who have chronic kidney disease and are on dialysis. The company said its partner FibroGen China, a subsidiary of FibroGen Inc. (FGEN), has received marketing authorization from the Chinese National Medical Products Administration for orally administered roxadustat.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Big Pharma Wins Drug Approval in China Ahead of West for First TimeChina has approved AstraZeneca and Fibrogen’s new anemia drug roxadustat, marking the first time a medicine from a global pharmaceutical company has received the green light there before any other market. meanwhile, US added to list of most dangerous countries for journalists. MAGA - epic fail Probably to make cheap knock off ...
Source: WSJ - 🏆 98. / 63 Read more »